Craig Crews

Craig Crews has a significant work experience in the field of biology, chemistry, and pharmacology. Craig has founded multiple companies including Siduma Therapeutics in 2021, Halda Therapeutics in 2019, and Arvinas in 2013. Additionally, they have held various roles at Yale University, starting in 1995, where they served as the John C. Malone Professor of Mol., Cellular, and Developmental Biology; Chemistry; Pharmacology. Craig Crews has also been involved in the establishment of the Yale Center for Molecular Discovery in 2003 and Proteolix, where they served as a Co-Founder until 2009.

Craig Crews has a strong educational background in the field of biochemistry and chemical biology. Craig began their academic journey in 1982 at the University of Virginia, where they pursued a Bachelor's degree in Chemistry. After completing their undergraduate studies in 1986, Craig continued their education at the University of Tübingen as a DAAD Fellow, focusing on Microbiology from 1986 to 1987. Craig then returned to Harvard University, where they earned a Doctor of Philosophy (Ph.D.) degree in Biochemistry from 1987 to 1992. Craig further advanced their studies at Harvard University, serving as a Cancer Research Institute Fellow and specializing in Chemical Biology from 1992 to 1995.